AXS Stock Recent News

Although the revenue and EPS for Axis Capital (AXS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Axis Capital (AXS) came out with quarterly earnings of $3.29 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $2.93 per share a year ago.

PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or "the Company") (NYSE: AXS) today announced financial results for the second quarter ended June 30, 2025. Commenting on the second quarter 2025 financial results, Vince Tizzio, President and CEO of AXIS Capital said: "AXIS delivered an excellent second quarter highlighted by record profitability and we continued our trend of strong performance, with 18.6% diluted book value per share growth over the pr.

Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file AXS-14 and Sunosi's failure in MDD studies, but ADHD data for Sunosi is encouraging. I estimate $3bn in peak revenues by the mid-2030s, which supports a Buy rating despite management's more ambitious projections.

Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2025 on Tuesday, July 29, 2025 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Peter Vogt, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Wednesday, July 30, 2025 at 8:30 a.m. ET.

AXIS Capital gains from a well-performing specialty insurance, reinsurance, as well as the accident and health portfolio.

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington.

AXS.PR.E preferred shares are undervalued, offering a 6.85% yield and trading at a wider spread than similar investment-grade peers. AXIS Capital Holdings Limited maintains strong credit ratings (A+/A, Baa3/BBB), supporting the safety and attractiveness of its preferred stock. Statistical and yield spread analysis shows AXS.PR.E underperforms peers without clear justification, suggesting a market mispricing.